Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

CHMP recommends Egranli for prophylaxis of Chemotherapy- induced Neutropenia- Teva

29-Sep-2014

On 25 September 2014, the Committee ...

CHMP recommends Lymphoseek for radiopharmacutical diagnosis- Navidea Biopharmaceuticals

29-Sep-2014

The Committee for Medicinal Products ...

CHMP recommends Rezolsta combination darunavir + cobicistat for HIV treatment- Janssen Cilag

29-Sep-2014

The Committee for Medicinal Products ...

CHMP recommends Trulicity (dulaglutide) for treatment of T2D- Eli Lilly

29-Sep-2014

The Committee for Medicinal Products ...

Survival results for Perjeta in CLEOPATRA study for metastatic Breast Cancer-Genentech/Roche

29-Sep-2014

Genentech announced final survival ...

Positive results from ASCEND-1 study for Zykadia in ALK+ Non Small Cell Lung Cancer- Novartis

28-Sep-2014

Novartis announced new data, from ...

Results of Afinitor in RADIANT -3 trial for Pancreatic Neuroendocrine Tumor- Novartis

28-Sep-2014

Novartis presented final results on ...

Recent Updates

Drugs

Clinical Guidelines

Early and locally advanced breast cancer: Diagnosis and treatment

Advanced breast cancer (update): Diagnosis and treatment

Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease

Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care

Medical Journals

Electronic cigarette use among patients with cancer: Characteristics of electronic cigarette users and their smoking cessation outcomes

Cancer survival in China, 2003-2005: A population-based study

Colorectal Cancer Prevention by an Optimized Colonoscopy Protocol in Routine Practice

Targeting hypoxia in the treatment of small cell lung cancer

epgonline.org Social